BRIEF-FDA approves Amgen's Parsabiv, first new treatment in more than a decade for secondary hyperparathyroidism in adult patients on hemodialysis
February 07, 2017 at 18:21 PM EST
* FDA approves Amgen's Parsabiv (etelcalcetide), first new treatment in more than a decade for secondary hyperparathyroidism in adult patients on hemodialysis
